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Patients with pulmonary infection often present with ventilation and perfusion abnormalities, which can impair 
intravenous antibiotic therapy. Intra-tracheal (IT) administration has met with obstacles, such as inadequate 
delivery to affected lung regions and the disruption of gas exchange. We hypothesized that IT administration of a 
gentamicin (G)/perfluorochemical (PFC) suspension (G/PFC) would effectively deliver and distribute gentamicin to 
the lung, while maintaining gas exchange and non-toxic serum levels. In addition, we sought to compare serum G 
and lung levels and distribution of G when GjPFC is administered at the initiation of partial liquid ventilation 
(PLV) vs. during PLV. To test this hypothesis, 17 newborn lambs were ventilated by PLV with perflubron 
(LiquiVent@) for 4 h using three different G (5 mg kg-‘) administration techniques: IT slow-fill (SF) (n=6; GjPFC 
over 15 min at start of PLV), IT top-fill (TF) (n=6; GjPFC lo-65 min after start of PLV), intravenous (IV) (n=5, 
aqueous injection at start of PLV). Serum levels of gentamicin were obtained 1, 15, 30 and 60 min after 
administration, and hourly thereafter for the remainder of the protocol (4 h). Arterial blood gas and pulmonary 
function measurements were obtained throughout the protocol. At the conclusion of the protocol, representative 
samples from each lung lobe, the brain and kidney were homogenized and assayed for gentamicin. All results are 
presented as the mean ~SEM; P<O,O5. Over time, serum gentamicin levels were greatest (PcO.05) in IV (11.02 
2.3 ,ng ml-‘), followed by TF (2.3AO.l pg ml-‘) and SF (O.S+O.l pg ml-‘). The percentage of the administered 
dose remaining in the lungs after 4 h was greater (P < 0.05) following IT delivery (SF 23.8 & 4.3 %, TF 13.7 + 2.5 %) 
as compared to IV (3.7kO.5 %). These findings suggest that for a given dose of G, both SF and TF delivery 
methods of GjPFC can enhance pulmonary, relative to systemic, antibiotic coverage. 
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Introduction 
Newborn infants receiving prolonged ventilation frequently 
present with pulmonary infection. Infection is often accom- 
panied by acute lung injury, leading to ventilation and 
perfusion abnormalities. Ventilation can be non-uniform and 
perfusion may be restricted in the infected regions. These 
abnormalities hamper conventional intravenous antibiotic 
therapy because the route of administration proves ineffec- 
tive in delivering the therapeutic agent to the site infection 
(1). This issue has prompted the examination of alternate 
routes for delivery of therapeutic agents to the lung. 
Pulmonary administration of drugs (PAD) has been 
explored as a method of bypassing the systemic circulation 
as a delivery route (2-6). However, this method has met 
with obstacles to delivery, such as problems with particle 
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size, ventilation abnormalities, uneven distribution of the 
drugs and impairments in respiratory gas exchange and 
pulmonary mechanics. 
Throughout the past 30 yr, perfluorochemical liquid 
ventilation (PFC LV) has been shown to improve 
pulmonary mechanics and gas exchange while supporting 
respiration in cases of acute lung injury (7-l 5). In addition 
to enabling the improvements in lung mechanics and 
respiratory gas exchange during PFC LV, the physical 
properties of perfluorochemical (PFC) liquids also make 
them an ideal vehicle for delivering biological agents to the 
lung (1621). The low surface tension of PFC liquids and 
the ability to recruit lung volume during PFC LV, allow for 
homogenous delivery of the drug throughout the lung. 
Pulmonary blood flow is more evenly distributed and 
ventilation-perfusion matching is improved in the liquid- 
filled lung (22-24). This provides a more effective exposure 
of the drug to the lung parenchyma and pulmonary 
circulation. The inert nature of PFC precludes any adverse 
vehicle-agent interaction. Importantly, PFC liquids have 
the unique ability to support gas exchange during the 
delivery of the biological agents (12,20). 
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Aqueous solutions are not readily soluble in PFCs. The 
previous studies utilizing LV for PAD achieved success 
while relying on bulk flow turbulent mixing for the delivery 
of the drug (19,20;25,26). Increasing the solubility of the 
drugs by suspending them in a PFC should provide a stable 
homogenous distribution of drug within the lung and better 
control of dosing procedures. In this study, we utilized a 
newly developed gentramicin/perfluorochemical (G/PFC) 
nanocrystal suspension (Alliance Pharmaceutical Corp.; 
San Diego, CA, U.S.A.) and evaluated its administration 
during partial liquid ventilation (PLV). Since many patients 
who require PLV for respiratory support often have co- 
existing pulmonary infection, we sought to evaluate the 
efficacy of various administration techniques of this GjPFC 
suspension either during the slow-fill (SF) initiation of PLV 
or during a top-fill (TF) procedure after PLV has already 
been initiated. These administration techniques were 
compared to conventional IV antibiotic delivery during 
PLV. We hypothesized that, compared to IV administra- 
tion of aqueous gentamicin, both SF and TF techniques for 
the administration of the GjPFC suspension would 
effectively deliver and distribute gentamicin to the lung. 
Methods 
VITRO TESTING 
In vitro experiments were performed on the GjPFC 
suspension (Alliance Pharmaceutical Corp.; San Diego, 
CA, U.S.A.) to evaluate drug stratification and the degree 
of agitation required to precipitate the release of the 
gentamicin from the GjPFC suspension. Since the GjPFC 
suspension contains a different PFC (perfluoro-N-butyl 
ethane) from the perflubron used for PLV, this experiment 
was performed to determine if there would be any 
stratification of the two PFC liquids in a fluid column (10 ml 
graduated glass cylinder, 20 cm in height), and hence in the 
lung, over time. The GjPFC suspension (3 mg G ml PFC-‘) 
was added to perflubron in several graduated cylinders. 
These graduated cylinders were fitted with catheters 
through which samples of the mixture were obtained from 
the top, middle and bottom of the Auid column over 4 h. 
The samples were added to saline and vortexed to extract 
the gentamicin into an aqueous layer, which was assayed 
for gentamicin. The gentamicin concentrations served as an 
indicator of any stratification of the GjPFC suspension and 
the perflubron in the fluid column. 
ANIMAL PREPARATION 
Twelve healthy newborn lambs (< 1 week old; weight = 
4.36 + 0.63 SE kg) were studied and managed according to 
the National Institutes of Health Regulations and the 
Guiding Principles in the Care and Use of Animals of the 
American Physiological Society. The study was performed 
with the approval of the institutional animal care commit- 
tee. Animals were anesthetized with intraperitoneal sodium 
pentobarbital(25 mg kg-‘); followed by local anesthesia of 
the ventral cervical area (0.5% lidocaine HCI). The animals 
were placed in the supine position. Arterial and venous 
catheters (5 FR) were placed in a carotid artery and jugular 
vein, respectively. The trachea was cannulated with a size 4 
or 5 Hi Lo Jet Tube (Mallinckrodt MedicalTM, St. Louis, 
MO, U.S.A.). The tip of the tube was positioned proximal 
to the carina. An ExosurfTM endotracheal tube adapter 
was placed at the end of the endotracheal tube, and the side 
port of the adapter used for GjPFC suspension adminis- 
tration. The lambs were connected to a time-cycled, 
pressure-limited ventilator (Specialized Laboratory Equip- 
ment, Ltd., Surry, U.K.) and paralyzed with pancuronium 
bromide (0.1 mg kg-‘). The inspiratory time was set at 0.5 
set and the fraction of inspired oxygen set at 1.0. These 
values were held constant for the duration of the experi- 
ment. Arterial blood samples were taken for blood gas 
analysis and serum gentamicin evaluation prior to and after 
GjPFC administration. In addition, pulmonary function 
measurements were obtained throughout the study (27). 
Ventilator pressures and rates were adjusted to maintain 
physiologic arterial blood gas measurements. 
EXPERIMENTAL PROTOCOL 
A. Partial liquid ventilation with top-fill (TF) 
gentamicin delivery 
Gentamicin (5 mg kg-‘) was instilled in one of three 
methods. For the TF group, a bolus of oxygenated 
perflubron (LiquiVen@: Alliance Pharmaceutical Corp., 
San Diego, CA, U.S.A.) was instilled by gravity through 
the endotracheal tube within 1 min to initiate PLV. The 
lambs were in the supine position at the initiation of PFC 
filling, and were rotated to the left, right and prone 
positions during the administration. Arterial blood chem- 
istry was evaluated and ventilator settings were adjusted to 
maintain physiological gas exchange. After 2918 SE 
minutes (range: lo-65 min) the bolus of GjPFC suspension 
(7.4$0,4 SE ml) was instilled within 1 min through the side 
port of the endotracheal tube adapter using a 10 ml syringe 
to simulate GjPFC suspension administration after PLV 
initiation. Again, drug administration was initiated with the 
lambs in the supine position. The lambs were then rotated 
to the left, right and prone position during administration. 
Time zero was defined as the initiation of administration of 
the gentamicin suspension. The total volume of perflubron 
and GjPFC suspension instilled gave a liquid functional 
residual capacity (FRC) of 20 ml kg-‘. 
B. Partial liquid ventilation with slow-fill (SF) 
gentamicin delivery 
For the SF group, the GjPFC suspension (7,1$0.5 SE ml) 
was combined with perfmbron to yield a total volume of 20 
ml kg-’ prior to pulmonary administration. The GjPFC 
suspension and perflubron solution was mixed with a 
vortex and followed by oxygenation with 100% O2 for 3 
min. The GjPFC suspension and perflubron solution was 
drawn into syringes (20 and 60 ml) and delivered through 
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the side port of the endotracheal tube adapter over 15 min. 
The animals were rotated during filling, spending 1-2 min 
in the prone, supine, left and right positions. Time zero was 
defined as the initiation of administration of the GjPFC 
suspension. This delivery technique was intended to 
simulate the combined initiation of PLV and gentamicin 
treatment. 
C. Partial liquid ventilation with intravenous (IV) 
gentamicin delivery 
For the IV group, 20 ml kg-’ of perflubron was instilled 
into the lungs within 1 min during conventional mechanical 
ventilation (initiation of PLV). The lambs were in the 
supine position at the initiation of filling, and were rotated 
to the left, right and prone positions during the adminis- 
tration. Arterial blood chemistry was evaluated and 
ventilator settings were adjusted to maintain physiological 
gas exchange. A 5 mg kg-’ dose of gentamicin was 
administered intravenously, within 1 min. In all cases, time 
zero was defined as the initiation of administration of the 
IV gentamicin. 
ANIMAL MANAGEMENT AND 
MEASUREMENTS 
Arterial and venous blood pressures (Athena type 9040, 
S&W Medico Teknik A/S, Albertslund, Denmark), arterial 
blood chemistry (Stat Profile 3, NOVA Biomedical, 
Waltham, MA, U.S.A.), blood glucose (Model 23A 
Glucose Analyzer, Yellow Springs Instrument Co., Yellow 
Springs, OH, U.S.A.), hemoglobin (OSM3 Hemoximeter@, 
Radiometer America, Cleveland, OH, U.S.A.), hematocrit 
and pulmonary mechanics (PedsLab, Medical Associated 
Services, Hatfield, PA, U.S.A.) were obtained 15 and 30 
min after gentamicin instillation and every 30 min there- 
after for the remainder of the protocol. Ventilator settings 
were adjusted to maintain physiological blood gases, Acid- 
base balance was maintained with sodium bicarbonate 
when base excess was less than 1.0 mEq 1-l. Fluid and 
electrolyte balance were maintained with an arterial 
infusion (IVAC 560) of heparinized 0.9% saline, and a 
venous infusion of 5 or 10% dextrose at 6 ml kgg’hh’. 
Maintenance doses of sodium pentobarbital (2.5 mg kg- ‘) 
and pancuronium bromide (0.1 mg kg-i) were adminis- 
tered intravenously as necessary. The animals were reposi- 
tioned every 30 min. 
Arterial blood samples (1.5-2 ml) were obtained for 
gentamicin measurements at 1, 15, 30 and 60 min after 
gentamicin delivery and every hour thereafter for the 
remainder of the protocol (4 h). The samples were collected 
in glass test tubes without serum separators or anti- 
coagulant, allowed to clot and centrifuged (Model HN-S, 
International Equipment Company, Needham Heights, 
Mass, U.S.A.) at 4000 rpm for 30 min. The serum was 
pipetted into 1.5 ml eppendorf tubes and assayed for 
gentamicin using a TDX Flex (Abbott Laboratories, 
Abbott Park, IL, U.S.A.). 
At the conclusion of the protocol, the animals were 
sedated deeply with sodium pentabarbital (3 ml IV) and 
killed with potassium chloride (10 ml IV). The lungs 
underwent gross examination, the trachea was clamped at 
end expiration and the lungs were block dissected. The 
pulmonary vasculature was perfused with normal saline 
through the pulmonary artery. The heart and trachea were 
dissected free. The entire brain and one kidney were 
obtained and weighed. The weights of the right and left 
lungs and each individual lobe were measured. One sample 
(l-2) from the brain, kidney and each lobe of the lung were 
obtained and weighed for wet to dry weight ratios. 
Representative samples (7-log) from each lobe, and the 
brain and kidney, were obtained and placed in separate 
50 ml tubes containing 15 ml phosphate buffer (pH 7.4) and 
homogenized. The homogenate was centrifuged (Damon 
CRV-5000, Needham Heights, Mass, U.S.A.) at 2000 rpm 
for 10 min. The supernatant was aspirated, pipetted into 
three 15 ml tubes and assayed for gentamicin. 
CALCULATIONS 
Tissue levels of gentamicin were normalized to dry weight. 
Using the gentamicin concentration from the lung super- 
natant assay, tissue levels of gentamicin per gram of dry 
tissue were determined as previously described (17) by the 
following equation: 
Tissue gentamicin(pg g-‘, dry wt) 
= [gentamicin (/*g/ml-‘)/sample weight (g)/ 
buffer volume (ml)]/[dry/wet ratio] (1) 
The concentration of gentamicin in each lobe, corrected 
to dry weight, was then expressed as a percentage of the 
mean gentamicin concentration for that group. Addition- 
ally, the concentrations of gentamicin remaining in each 
lobe, the kidneys and the brain, were used to calculate the 
amount of gentamicin remaining in each lobe, the kidneys 
and the brain by Equation 2. The amounts of gentamicin 
from each lobe were then summed to express the amount of 
gentamicin in the entire lung. 
Amount of gentamicin (pg) = gentamicin concentration 
(pg g-’ dry wt) x lobe weight (g dry wt.) (2) 
The percentage of the administered does remaining in 
each lobe of the lung was calculated as previously described 
(17) by the following equation: 
Percentage of administered dose 
= [gentamicin (bg g-’ dry wt.) x dry lobe wt. (g)]/ 
[administered dose (pg)/total dry lung wt. (g)] x 100 
(3) 
STATISTICAL ANALYSIS 
Results are presented as mean + standard error of the 
mean (SEM). Two-factor analyses of variance (ANOVA) 
with repeated measures and post hoc testing using the 
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Bonnferroni/Dunn all means test were performed to 
evaluate statistical differences in gentamicin serum and 
tissue levels, gas exchange, acid-base function, cardiovas- 
cular function and pulmonary mechanics as a function of 
time. In addition, paired and unpaired Student’s t-tests 
were performed to determine statistical differences within 
groups over time and between groups at individual time 
points, respectively. Significance was accepted at the 
PcO.05 level. 
Results 
IN VITRO STUDIES 
The agitation experiments revealed that vortexing (opposed 
to no agitation or gentle agitation with a rocker table) of 
the GjPFC suspension in saline for 3 min resulted in 
optimum extraction of gentamicin into saline. It was also 
found that there was no difference in gentamicin extraction 
between 25” and 37°C. 
Stratification studies performed in vitro, also demon- 
strated no significant changes in gentamicin concentration 
along the 20 cm fluid column or as a function of time (4 h). 
The gentamicin levels ranged from (2,15+0.24 SE pg ml-‘; 
top), (2.19+0.12 SE pg ml-‘; middle), to (2.38+0,08 SE ,ug 
ml -I; bottom) and were similar at 30 min, 1, 2, 3 and 4 h. 
This measured variation was within the 10% calibration 
resolution of the gentamicin assay. 
Finally, residual gentamicin tests of the delivery syringe 
or the endortacheal tube, showed that less than 1.5% of the 
original dose were found in either apparatus, allowing the 
assumption that gentamicin delivery to the lung was at least 
97% efficient. 
PHYSIOLOGICAL DATA 
Table 1 summarizes arterial blood chemistry results 
between groups. As shown, PaC02, pH and PaOz were 
maintained in the physiological range throughout the 
protocol, with only the PaOz in the SF group 
(366.0 _+ 14.7 SE) being significantly greater (PC 0.05) than 
in the IV group (311.7+ 16.9 SE). Within each group there 
were significant differences (P < 0.05) as a function of time 
and independent of group, with the 15 min time point being 
significantly greater for PaC02 (47.6k2.9 SE mmHg) and 
significantly less for pH (7.35fO.02 SE) and PaOz 
(189.2k32.6 SE mmHg) than all other time points. 
Table 2 shows summarized pulmonary function results 
between the three groups over the duration of the 4 h 
protocol. There were no significant differences (P < 0.05) in 
a/A between groups, but there were as a function of time. 
Compared to baseline gas ventilation, all three groups 
showed a significant decrease in a/A at the 15 min time 
point, following instillation of PFC. Both IV and SF 
returned to steady within 15 min and TF returned within 30 
min. Mean airway pressure (PAW) was significantly greater 
(PcO.05) in TF (lO.l+O.l cm HzO) than both IV (7,4&O. 
2cm H20) and SF (8.0&0.2 cm H20), and SF was greater 
than IV. Compared with IV (1798 k34.0 ml min-’ kg-‘), 
minute ventilation (Vn) was significantly lower (P<O.O5) 
than both SF (229.5k8.5 ml mm’ kg-‘) and TF 
(242.6* 10.9 ml min-’ kg-‘). There were no differences 
TABLE 1. Summarized arterial blood chemistry following intravenous (IV), slow-fill and top-fill methods of gentamicin 
administration (mean k SE for 4 h protocol) 
Group IV Slow-fill Top-fill 
PaCOz(mmHg) 36.8 + 1.3 39.1 I 0.9 36.6 + 1.4 
PH 7.41 + 0.01 7.42 + 0.01 I.43 * 0.01 
PaCOz(mmHg) 311.7 $ 16.9” 366.0 & 14.7* 321.1 + 21.0 
* (P<O.O5). 
TABLE 2. Summarized pulmonary function profile following intravenous (IV), slow-fill and top-fill methods of gentamicin 
administration (mean + SE for 4 h protocol) (a/A: arterial/alveolar PO2 ratio; PAW: mean airway pressure; VE: minute 
ventilation) 
Group IV Slow-fill Top-fill 
al A 
Compliance (ml cmHzO- ’ kg- ‘) 
PAW (cmHzO) 
VE (ml mini kg-‘) 
* (P<O.O5). 
0.502 i 0,026 0.564 f 0.021 0.501 * 0.030 
1.00 f 0.05 1.00 * 0.22 0.79 & 0.04 
7.4 + 0.2" 8.0 i 0,2* 10.1 + 0.1” 
179.8 + 34" 229.5 & 8.5 242.6 I: 10.9 
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in either MAP or Vu as a function of time, nor in 
compliance between groups or as a function of time. 
Table 3 shows the cardiovascular data for all three 
groups. There was a statistical difference in heart rate (HR) 
between groups: IV had a significantly lower (P < 0.05) HR 
(177.8f6.6 SE bpm) than SF (210.9f4.4 SE bpm) and TF 
(226.15 3.1 SE bpm). Additionally, there was a statistical 
difference in mean blood pressure (MBP): TF had a 
significantly greater (P~0.05) MBP (78.9k1.3 SE) than 
IV (73.3 & 2.4 SE). There were no significant differences in 
HR nor in MBP as a function of time. 
GENTAMICIN SERUM LEVELS 
Figure 1 shows the serum gentamicin levels obtained as a 
function of administration technique and time. There was a 
significant difference (P < 0.05) in mean gentamicin serum 
levels between groups and independent of time, with IV 
having significantly higher levels (11.0 + 2.3 SE pg ml- ‘) 
than TF (2.3 iO.1 SE pg ml-‘) which was significantly 
higher than SF (08 f0.1 SE pg ml-‘) over time. Addition- 
ally, there was a significant difference (P<O.O5) between 
TABLE 3. Summarized cardiovascular function profile 
following intravenous (IV), slow-fill and top-fill methods 
of gentamicin administration (mean f SE for 4 h protocol) 
(MBP: mean blood pressure; HR: heart rate). 
Group IV Slow-fill Top-fill 
MBP (mmHg) 73.3 + 2.4* 74.6 + 1.3 78.9 + 1.3* 
HR @pm) 177.8 k 6.6* 210.9 + 4.4 226.1 _+ 3.1 
* (P-cO.05). 
50 , 
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FIG. 1. Serum gentamicin concentrations over time for 
intravenous (IV), slow-fill (SF) or top-fill (TF) 
administration of gentamicin. Inset: expanded view of 
serum gentamicin concentrations for SF and TF 
administration (mean + s~)*P<O.05. -A-: IV; -O-:slow- 
fill; -.-:top-fill. 
each of the groups as a function of time. The highest 
observed serum level in IV was 43.1 f2.6 SE pg ml-’ and 
occurred at the 1 min time point. The serum gentamicin 
levels decayed for the remainder of the protocol, with each 
successive time point significantly lower (P < 0.05) than the 
previous. The highest observed serum level in TF was 
3.5kO.3 SE /,Lg ml-’ and occurred 15 min after administra- 
tion. This concentration of gentamicin at 15 min was 
significantly different (P< 0.05) than at all other time 
points, with the exception of the 1 min point. The serum 
gentamicin levels in SF did not show a definable peak, and 
there was no significant difference in gentamicin levels 
between time points after 30min. A unpaired t-test 
demonstrated that IV serum gentamicin levels remainded 
higher than both TF and SF for the entire protocol; 
however, there was no significant difference (P<O.O5) 
between SF and TF by the end of the 4 h protocol. 
GENTAMICIN TISSUE LEVELS 
Figure 2 illustrates the amount of gentamicin remaining 
in the lungs, kidneys and brain. There was a significant 
difference (P < 0.05) in the amount of gentamicin remaining 
in lungs, kidneys and brains at the end of the protocol, with 
the lungs (512.7+ 108.2 SE pg) containing a greater amount 
than the kidneys (294.4f42.0 SE ,ug), which contained a 
greater amount than the brain (11.3 f2.9 snpg). 
An unpaired Student’s t-test demonstrated that the lungs 
of the IV group (96.5 f 13.6 SE pg) contained significantly 
less (P < 0.05) gentamicin than both the SF (903.2 f 200.0 
SE pg) and TF (468.9 + 80.8 SE pg) groups. It is noteworthy 
that there was no significant difference in lung gentamincin 
amounts between the SF group and the TF group. 
Additionally, there were no further statistical differences 
between groups for kidney or brain amounts of gentamicin. 
Table 4 summarizes the lung tissues gentamicin levels, 
presented as the percentage of the total original dose and 
Lungs Kidneys BEIin 
FiG. 2. Tissue amounts of gentamicin following 
intravenous (IV), slow-fill (SF) or top-fill (TF) 
administration of gentamicin. Note: including all groups, 
mean dry lung weight=40.35 + 4.56 SE g, mean dry weight 
of kidneys=6.01 f 1.14 SE g, mean dry brain 
weight=9,20f 1.15 SE g. 0: IV; ~4: SF; n : TF. 
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TABLE 4. Percentage of original dose remaining in lobes, 
corrected for dry weight after 4 h (mean + SEM) CA: cranial 
apical; RUL: right upper lobe; RML: right middle lobe; 
RLL: right lower lobe; LUL: left upper lobe; LLL: left 
lower lobe 
Group IV Slow-fill Top-fill 
CA 2.6 + 0.6 8.9 f 2.9 4.2 + 1.6 
RUL 2.2 * 0.3 24.4 5 7.6 3.5 & 0.8 
RML 2.6 i 0.9 10.0 * 5.5 3.1 * 1.3 
RLL 5.5 & 1.1 47.9 ) 10.0 27.2 + 5.9 
LUL 2.4 f 0.6 29.2 i 12.5 9.8 * 2.1 
LLL 6.6 & 1.5 49.3 f 9.9 34.3 * 4.9 
Mean 3.7 Ifr 0.5” 28.3 + 4.3* 13.7 f 2.5* 
* (P<O.O5). 
corrected for dry weight, remaining in each lobe of the 
lungs at the end of the protocol. Compared with TF 
(13.7k2.5 SE %), SF (28.3f4.3 SE %) resulted in a 
significantly higher (P < 0.05) percentage of the delivered 
dose of gentimicin remaining in the lungs 4 h after 
administration. Furthermore, both SF and TF resulted in 
a significantly higher (P<O.O5) percentage of the dose 
remaining than IV (3.7 kO.5 SE %). 
GENTAMICIN DISTRIBUTION 
The lobar distribution of gentamicin for each group is 
depicted in Fig. 3. The concentration of gentamicin in each 
lobe is presented as the percentage of the mean gentamicin 
concentration for the lung in that group. ANOVA 
demonstrated no significant differences between lobes. 
However, post hoc analysis indicated that there were 
significant differences between lobes in the IV (Fig. 3a) 
and SF (Fig. 3b) groups. In the IV groups, this difference 
was due to the cranial apical lobe being significantly greater 
(P<O.O5) than all other lobes except the right upper lobe. 
In the SF group, the right upper lobe was significantly 
greater (PcO.05) than all other lobes. Post hoc analysis did 
not demonstrate any significant differences between lobes in 
the TF group [Fig. 3c), thus indicating the most uniform 
distribution pattern. 
Discussion 
Neonates with pulmonary infection often present with 
ventilation and perfusion abnormalities. These abnormal- 
ities pose a barrier to conventional intravenous antibiotic 
therapy. The perfusion abnormalities limit delivery of the 
antibiotic to the infected site. Increasing the dose to 
improve delivery risks systemic toxicity. Additionally, 
delivery of the drugs to the lung parenchyma by aero- 
solization is less than optimal due to the impaired 
ventilation in the atelectatic and infected areas (2,3). 
Aerosolization or intratracheal (IT) instillation of 
250 - 
B * 
CA RUL RML RLL LUL LLL 
(b) CA RUL RML RLL LUL LLL 
250 
0 
Cc) CA RUL RML RLL LUL LLL 
Fio. 3. (a) Percentage of mean gentamicin concentration 
in the lung following intravenous (IV) administration. 
Values are presented for each lobe of the lung: CA: cranial 
apical lobe; RUL: right upper lobe; RML: right middle 
lobe; RLL: right lower lobe; LUL: left upper lobe; LLL: 
left lower lobe; *Significant (PcO.05) vs. all lobes, except 
RUL. IV mean concentration: 3.3 pg g-i. (b) Percentage 
of mean gentamicin concentration in the lung following 
slow-fill (SF) administration. Values are presented for 
each lobe of the lung: CA: cranial apical lobe; RUL: right 
upper lobe; RML: right middle lobe; RLL: right lower 
lobe; RLL: right lower lobe; LUL: left upper lobe; LLL: 
left lower lobe. *Significant (PiO.05) vs. all lobes. SF: 
mean concentration=32.1 pg g-i. (c) Percentage of mean 
gentamicin concentration in the lung following top-fill 
(TF) administration. Values are presented for each lobe of 
the lung: CA: cranial apical lobe; RUL: right upper lobe; 
RML: right middle lobe; RLL: right lower iobe; RLL: 
right lower lobe; LUL: left upper lobe; LLL: left lower 
lobe. TF: mean concentration=13.1 pg g-l. 
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antibiotics can disrupt normal gas exchange, which is 
usually impaired and of vital importance in cases of acute 
respiratory distress and infection. Delivery of aqueous 
gentimicin during PLV has demonstrated improved deliv- 
ery and distribution of the drug to the infected regions of 
the lung while maintaining effective gas exchange 
(16,17,21). Due to the relative insolubility of aqueous 
gentamicin in PFC, it was hypothesized that a GjPFC 
suspension would result in effective delivery and distribu- 
tion within the lung parenchyma. In this study, two 
techniques of IT administration of a GjPFC suspension 
were studied. These two techniques were compared with 
each other and to IV administration of aqueous gentamicin 
during PLV. This study demonstrates that a GjPFC 
suspension can be effectively administered with the initial 
dose of perflubron (SF) or while PLV is in progress (TF). 
Delivery 
The primary objective of pulmonary administration of 
gentamicin is to obtain sufficient lung parenchyma levels of 
the antibiotic and achieve a uniform distribution through- 
out the lung, while maintaining serum concentrations below 
toxic levels and providing control of the administered dose. 
Both methods of IT administration of the GjPFC suspen- 
sion resulted in considerably higher gentamicin levels in the 
lung, per gram of dry tissue (SF, 32.1 pg g-’ TF, 13.1 pg 
g-l), as compared to IV administration of aqueous 
gentamicin (3.3 pg g-l). This was expected, since IT 
administration delivers the drug directly to the target organ 
and IV administered gentamicin‘ is exposed to the entire 
systemic circulation, and must rely on the pulmonary 
circulation for lung exposure. 
There was a disparity between the two IT administration 
groups with respect to lung gentamicin levels at the 
conclusion of the experiment. This difference stems from 
the different administration techniques. In the SF group, the 
PFC and gentamicin were delivered gradually, over 15min. 
The effects of PFC on the lung, primarily lung volume 
recruitment, also occurred gradually. Additionally, the 
amount of gentamicin exposed to the large surface area of 
the alveolar-capillary barrier increased slowly. In contrast, 
the dose of PFC was administered to the TF group 
approximately 30 min prior to gentamicin administration. 
The gentamicin dose in the TF group was delivered within 
1 min, so the entire dose administered to the TF group was 
more rapidly exposed to the alveolar-capillary barrier and the 
lung parenchyma as compared to the SF group. Further- 
more, since the PFC dose was delivered to the animals of the 
TF group prior to gentamicin administration, there was a 
substantial amount of time for lung volume recruitment to 
occur. Thus, compared to the SF group, the gentamicin dose 
in the TF group was delivered over a shorter duration to 
lungs in which more lung volume recruitment had occurred. 
Due to the increased exposure to this extensive surface area, 
the flux of gentamicin from the lung parenchyma to the 
pulmonary vasculature was greater in the TF group as 
compared to the SF group. By the conclusion of the protocol, 
considerably more of the gentamicin dose in the TF group 
had entered the systemic circulation, so there was less 
gentamicin remaining in the lung. 
Serum 
The elevated lung levels observed following intratracheal 
administration of the GjPFC suspension were achieved 
without concomitant elevations in serum levels. The serum 
gentamicin profiles were different for each method of 
gentamicin administration. The peak serum levels observed 
were 3.48 + 0.26 SE pg ml- ’ for TF and 1.06 f 0.24 SE yg ml- ’ 
for SF. These levels are well below the reported 12 ugml-’ 
concentration for systemic toxicity (28). The peak serum 
level observed in IV was 43.1Ok2.58 SE pg ml-’ min 
following administration. Furthermore, at 4 h, there was no 
difference between serum levels in the SF and TF groups, 
but the IV group had significantly higher serum gentamicin 
levels than both the SF and TF groups. 
In addition to intra-tracheal administration resulting in 
much lower serum levels than IV administration there were 
also differences between the serum profiles of the two IT 
administration groups. Serum levels of gentamicin were 
significantly greater in the TF group than the SF group 
(Fig. 1 -inset). This difference remained for the first 3 h of 
the protocol. By the end of the 4 h protocol, however, there 
was no statistical difference in gentamicin serum levels 
between the IT groups. Serum uptake of gentamicin from 
the lungs was different for each group. As expected, IV 
administration resulted in an exponential decay of the 
serum gentamicin. The serum gentamicin level in the TF 
group increased for the first 15 min and then decayed. The 
dynamics of the serum gentamicin levels in the SF group 
were also different. At 1 min, the gentamicin level was not 
significantly different from baseline, which was in contrast 
to the TF group. We reasoned that this was due to the fact 
that, at 1 min, only one fifteenth of the dose had been 
delivered to the SF group. The TF group had received its 
entire dose by 1 min. Because the TF group received its 
entire dose within 1 min, the entire volume of the 
gentamicin suspension spent a longer period of time 
exposed to the extensive surface area of the lungs, as 
compared to the SF group. Thus, there was a much greater 
opportunity for the diffusion of gentamicin across the 
alveolar-capillary barrier and into the circulation. 
Distribution 
One of the advantages of administering biological sub- 
stances with PFC liquid during PLV is to take advantage of 
the unique physicochemical properties of the PFC. By 
eliminating the air-liquid interface in the lung, PFC liquids 
reduce the surface tension in the lung. It has been well 
demonstrated that PFC liquids distribute to peripheral and 
under-inflated regions of the lung (11, 15, 19, 20). In doing 
so, they have shown to relieve areas of atelectasis in injured 
lungs (29,30). By distributing to the lung periphery, and re- 
inflating any atelectatic regions, PFC liquid should 
optimize the delivery and distribution of biological 
substances administered with them to all regions of the lung 
parenchyma. 
In this study, all three groups consisted of animals with 
normal lungs. Since normal lung mechanics are optimal, we 
did not expect to see differences in the overall level of 
gentamicin distribution between the various methods of 
administration. Among each of the groups, as seen in 
Fig. 3, we observed a relatively equal level of distribution of 
gentamicin between lung lobes. 
BIODISTRIBUTION OF GENTAMICIN 
The low serum levels observed following the administration 
of the GjPFC suspension lead to the question as to whether 
the gentamicin is actually being delivered to the lung 
parenchyma, as opposed to remaining bound to the PFC. 
The in vitro experiments studying the release of the 
gentamicin into an aqueous saline layer demonstrated that 
short-term agitation (3 min of vortexing) resulted in 
extraction of the gentamicin from the suspension. We 
believe that the agitation occurring with ventilation and 
lung expansion over time is sufficient to promote the release 
of gentamicin. Additionally, this agitation and mixing 
associated with ventilation is also sufficient to mix the G/ 
PFC suspension and perflubron to prevent any stratifica- 
tion of the different PFC liquids. This, combined with the 
results of the in vitro fluid column experiment indicating 
minimum stratification, lead us to conclude that the 
antibiotic is homogeneously mixed within the PFC suspen- 
sion. Thus, all lung regions exposed to the suspension were 
equally exposed to the antibiotic. 
CONCLUSION 
Pulmonary administration of gentamicin as a GjPFC 
suspension is an effective means of administering the 
antibiotic to the lung. This study demonstrates that the 
drug is delivered to the lung parenchyma while maintaining 
safe serum levels. This study used a single 5 mg kg-’ dose 
of gentamicin. Dosing strategies can be applied to obtain 
desired lung and serum levels. Furthermore, we have 
demonstrated the efficacy of administering the antibiotic 
at any stage of the PLV treatment plan. The gentamicin 
suspension can be administered with the initial dose of 
PFC, or while the patient is undergoing PLV. 
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